Terms: = Prostate cancer AND ATP2B3, PMCA3, 492, ENSG00000067842 AND Treatment
49 results:
1. Decision aids for people facing health treatment or screening decisions.
Stacey D; Lewis KB; Smith M; Carley M; Volk R; Douglas EE; Pacheco-Brousseau L; Finderup J; Gunderson J; Barry MJ; Bennett CL; Bravo P; Steffensen K; Gogovor A; Graham ID; Kelly SE; Légaré F; Sondergaard H; Thomson R; Trenaman L; Trevena L
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD001431. PubMed ID: 38284415
[TBL] [Abstract] [Full Text] [Related]
2. Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life.
Lebret T; Bonastre J; Fraslin A; Neuzillet Y; Droupy S; Rebillard X; Vordos D; Guy L; Villers A; Schneider M; Coloby P; Lacoste J; Méjean A; Lacoste J; Descotes JL; Eschwege P; Loison G; Blanché H; Mariani O; Ghaleh B; Mangin A; Sirab N; Groussard K; Radvanyi F; Allory Y; Benhamou S
BMJ Open; 2023 Dec; 13(12):e075942. PubMed ID: 38128940
[TBL] [Abstract] [Full Text] [Related]
3. Metabolic Syndrome is Associated with prostate cancer Diagnosed on Biopsy but not the Gleason Score and the Number of cancer-Positive Cores: A Prospective Controlled Study.
Bayraktar Z; Şahin C; Yıldırım S; Karaca Y; Sinanoğlu O
Arch Esp Urol; 2023 Sep; 76(7):504-510. PubMed ID: 37867335
[TBL] [Abstract] [Full Text] [Related]
4. Comparison of treatment costs for primary localized prostate cancer in Austria and Vienna: an economic analysis.
Moll M; Goldner G
Front Public Health; 2023; 11():1016860. PubMed ID: 37325333
[TBL] [Abstract] [Full Text] [Related]
5. African American vs Caucasian race/ethnicity in adrenocortical carcinoma patients.
Panunzio A; Tappero S; Hohenhorst L; Cano Garcia C; Piccinelli M; Barletta F; Tian Z; Tafuri A; Briganti A; De Cobelli O; Chun FKH; Tilki D; Terrone C; Saad F; Shariat SF; Bourdeau I; Cerruto MA; Antonelli A; Karakiewicz PI
Endocr Relat Cancer; 2023 Jul; 30(7):. PubMed ID: 37043366
[TBL] [Abstract] [Full Text] [Related]
6. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Saad F; Efstathiou E; Attard G; Flaig TW; Franke F; Goodman OB; Oudard S; Steuber T; Suzuki H; Wu D; Yeruva K; De Porre P; Brookman-May S; Li S; Li J; Thomas S; Bevans KB; Mundle SD; McCarthy SA; Rathkopf DE;
Lancet Oncol; 2021 Nov; 22(11):1541-1559. PubMed ID: 34600602
[TBL] [Abstract] [Full Text] [Related]
7. How Much Reliable Is the Current Belief on Grade Group 1 prostate cancer?
Chung MS; Choi YJ; Lee YS; Yoon BI; Ha US
Pathol Oncol Res; 2021; 27():629489. PubMed ID: 34257593
[No Abstract] [Full Text] [Related]
8. The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy.
Wang Y; Wu G; Fan L; Pan J; Gong Y; Fei X; Du X; Zhu Y; Xue W
Prostate; 2021 Jun; 81(8):463-468. PubMed ID: 33822399
[TBL] [Abstract] [Full Text] [Related]
9. Reduction of inter-observer contouring variability in daily clinical practice through a retrospective, evidence-based intervention.
Patrick HM; Souhami L; Kildea J
Acta Oncol; 2021 Feb; 60(2):229-236. PubMed ID: 32988249
[TBL] [Abstract] [Full Text] [Related]
10. Knockdown of FBP1 enhances radiosensitivity in prostate cancer cells by activating autophagy.
Li XR; Zhou KQ; Yin Z; Gao YL; Yang X
Neoplasma; 2020 Sep; 67(5):982-991. PubMed ID: 32453596
[TBL] [Abstract] [Full Text] [Related]
11. Co-occurrent Alterations of Alzheimer's Genes and prostate cancer Genes in prostate cancer.
Lehrer S; Rheinstein PH
Cancer Genomics Proteomics; 2020; 17(3):271-275. PubMed ID: 32345668
[TBL] [Abstract] [Full Text] [Related]
12.
Khreish F; Ebert N; Ries M; Maus S; Rosar F; Bohnenberger H; Stemler T; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):721-728. PubMed ID: 31758224
[TBL] [Abstract] [Full Text] [Related]
13. Association of sociodemographic and clinical variables with time to start prostate cancer treatment.
Sacramento RS; Simião LJ; Viana KCG; Andrade MAC; Amorim MHC; Zandonade E
Cien Saude Colet; 2019 Sep; 24(9):3265-3274. PubMed ID: 31508747
[TBL] [Abstract] [Full Text] [Related]
14. The impact of PTEN deletion and ERG rearrangement on recurrence after treatment for prostate cancer: a systematic review and meta-analysis.
Liu R; Zhou J; Xia S; Li T
Clin Transl Oncol; 2020 May; 22(5):694-702. PubMed ID: 31359337
[TBL] [Abstract] [Full Text] [Related]
15. Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men.
Moustsen IR; Larsen SB; Duun-Henriksen AK; Tjønneland A; Kjær SK; Brasso K; Johansen C; Dalton SO
Br J Cancer; 2019 May; 120(11):1067-1074. PubMed ID: 31065112
[TBL] [Abstract] [Full Text] [Related]
16. Extensive Histological Sampling following Focal Therapy of Clinically Significant prostate cancer with High Intensity Focused Ultrasound.
Mortezavi A; Krauter J; Gu A; Sonderer J; Bruhin J; Reeve KA; Held L; Donati OF; Rupp NJ; Moch H; Sulser T; Eberli D
J Urol; 2019 Oct; 202(4):717-724. PubMed ID: 31042109
[TBL] [Abstract] [Full Text] [Related]
17. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study.
Büchser D; Casquero F; Espinosa JM; Perez F; Minguez P; Martinez-Indart L; Suarez F; Gonzalez A; Cacicedo J; San Miguel I; Maleta A; Gomez-Caamaño A; Bilbao P; Gomez-Iturriaga A
Radiother Oncol; 2019 Jun; 135():13-18. PubMed ID: 31015158
[TBL] [Abstract] [Full Text] [Related]
18. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
Krasnow RE; Rodríguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
[TBL] [Abstract] [Full Text] [Related]
19. Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk prostate cancer (SATURN): Early Toxicity and Quality of Life.
Musunuru HB; D'Alimonte L; Davidson M; Ho L; Cheung P; Vesprini D; Liu S; Chu W; Chung H; Ravi A; Deabreu A; Zhang L; Commisso K; Loblaw A
Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1438-1447. PubMed ID: 30071295
[TBL] [Abstract] [Full Text] [Related]
20. Metabolic syndrome and smoking are associated with an increased risk of nocturia in male patients with benign prostatic enlargement.
De Nunzio C; Brassetti A; Proietti F; Deroma M; Esperto F; Tubaro A
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):287-292. PubMed ID: 29203892
[TBL] [Abstract] [Full Text] [Related]
[Next]
